Alzinova AB · OMXSTO:ALZ
Alzinova AB — Investor Presentation (December 2023)
34 slides from Alzinova AB's investor presentation, Dec 5, 2023
Slide 1: Alzinova Company presentation December 2023
We will make it possible for Alzheimer's patients Alzinova to live an independent and active life Company presentation | December | 2023 ©2023 Alzinova AB (publ), All rights reserved
Slide 2: Forward looking statements
Forward looking statements This information contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strate
Slide 3: Imagine if there was a vaccine against Alzheimer's disease
Imagine if there was a vaccine against Alzheimer's disease ©2023 Alzinova AB (publ), All rights reserved
Slide 4: Alzinova is developing the first specific vaccine against Alzheimer's disease
Swedish biopharma company | Based in Gothenburg Founded 2011 Alzinova is High unmet medical need for Alzheimer’s disease developing the – huge market opportunity first specific Innovative science & proprietary technology enables development of vaccine against disease-modifying treatments for Alzheim
Slide 5: Alzheimer's disease
Alzheimer’s disease • Slowly progressing disease • Caused by toxic formations in the brain called oligomers – consists of Aβ-42 peptide • Destroys brain structures Memory Delusions Loss of loss, & poor Depression Agitation independent Cause of confusion judgement life death • Need for targeted treat
Slide 6: Alzheimer's disease – huge unmet medical need
Alzheimer’s disease – huge unmet medical need Dementia >55 million people suffer from dementia Impacts >150 million people in 2050 quality of life US $1.3 trillion (US $2.8 trillion by 2030) Patients, families, Annual cost care givers 60-70% are Alzheimer’s patients World Alzheimer’s Report 2015, 20
Slide 7: Unmet medical need
Cognitive and physical decline, leads to increased Individual dependency on caregiving and later full-time care. Unpaid family and friend caregivers can experience Caregiver physical, financial & emotional strains. Unmet Elderly care requires institutionalized housing, managing medical need Hospital
Slide 8: >100 million people will suffer from Alzheimer's in 2050
>100 million people will suffer from Alzheimer’s in 2050 ©2023 Alzinova AB (publ), All rights reserved
Slide 9: Enormous market potential
Enormous market potential Alzheimer’s therapeutics market > US $13 billion by 2028 Substantial market 2 out of 7 predicted blockbusters by 2026 are new anti-Alzheimer’s drugs with US $1.7 - 4.5 billion projected annual revenue potential for Alzinova Market growth driven by introduction of novel ther
Slide 10: Potential breakthrough in Alzheimer's
Potential breakthrough in Alzheimer’s ✓ ✓ ✓ High unmet medical & market potential for disease-modifying treatments of Alzheimer’s disease Short-term goal: Mid-term goal: Long-term goal: First clinical trial targeting ALZ-101 Enter Phase 2 in 2024 Bring to market in oligomers with a therapeutic
Slide 11: Alzinova's business model – develop, document, prepare, partner & bring to market
Develop breakthrough disease-modifying treatments based on proprietary AβCC technology Document safety and tolerability in patients with Alzheimer’s disease Alzinova’s business model – develop, document, Prepare (in parallel) for phase 2 to optimize the candidates value prepare, partner & bring to m
Slide 12: Our candidates for treating Alzheimer's disease
Our candidates for treating Alzheimer’s disease ©2023 Alzinova AB (publ), All rights reserved
Slide 13: AβCC peptide technology enables high precision targeting of toxic oligomers
Alzinova’s AβCC peptide™ technology enables high precision, with antibodies specifically targeting the toxic oligomers Aβ – amyloid-beta ©2023 Alzinova AB (publ), All rights reserved
Slide 14: Two differentiated, oligomer-specific products based on the same proprietary technology
Two differentiated, oligomer- specific products based on the same proprietary technology • Highly specific disease modifying treatments, directed towards the toxic accumulations of amyloid beta in the brain • Opportunity to become effective and well tolerated treatments to halt and prevent Alzheimer
Slide 15: ALZ-101 represents a potential breakthrough in treating Alzheimer's Disease
ALZ-101 represent a potential breakthrough in treating Alzheimer's Disease • The body generates specific antibodies against toxic oligomers ALZ-101 vaccine • High patient compliance (few booster doses) • Long-acting • Preventive treatment possible • Large potential patient population ©2023 Alzinova
Slide 16: ALZ-201 a complement to the vaccine ALZ-101
ALZ-201 a complement to the vaccine ALZ-101 in treating Alzheimer's Disease • Unique binding profile for targeting toxic oligomers ALZ-201 monoclonal antibody • Several potential uses for the antibody: − complement to the vaccine ALZ-101 for patients who, for various reasons, need higher levels of a
Slide 17: Improving quality of care – for more patients
Improving quality of care – for more patients X1 X 50 Based on Swedish healthcare system, and that the two treatments have equivalent clinical efficacy, total treatment duration and drug cost. Sources: SCB Statistics Sweden, Swedish regional healthcare cost ©2023 Alzinova AB (publ), All rights reser
Slide 18: Alzinova's product pipeline offers complementary ways to fight Alzheimer's Disease
Alzinova's product pipeline offers complementary ways to fight Alzheimer’s Disease Candidates Discovery Pre-clinical Clinical NDA/MAA Next Major Milestone ALZ-1011) therapeutic Positive top-line data Q1 2024, Full analysis of part A vaccine November 2023 clinical phase 1b ALZ-2012) monoclonal antibo
Slide 19: What if there was a vaccine for Alzheimer's?
What if there was a vaccine for Alzheimer's? Alzinova Other actors Targeted treatment – oligomer specific Target plaques Vaccine Non-specific treatments Antibody - as a complement to the vaccine Often complicated drug treatments Fast, effective and uncomplicated Unlikely to be sufficiently effecti
Slide 20: ALZ-101 – favorable profile with best-in-class opportunity
ALZ-101 – favorable profile with “best-in-class” opportunity ALZ-101 Donanemab Lecanemab Companies Alzinova Eli Lilly BioArctic/Eisai/Biogen Primary target Aβ oligomers plaque (P-Glu3-Aβ) Aβ monomers/fibrils/oligomers –> good efficacy +++ (potential) + + Compliance +++ + + Low cost* +++ ++ + Low soc
Slide 21: ALZ-101 & ALZ-201 are patented through two patent families
ALZ-101 & ALZ-201 are patented through two patent families Stable amyloid-beta monomers and oligomers (ALZ-101) Region/Country Patent number Status Expiry date Australia 2009236699 Granted 2029-04-14 Europe(1) 2262526 Granted 2029-04-14 Japan 5817060 Granted 2029-04-14 We maintain an Japan 6128450 G
Slide 22: Strong data supports clinical development of ALZ-101
Strong data supports clinical development of ALZ-101 Comprehensive pre-clinical results ALZ-101 is well tolerated in non-clinical safety and toxicity studies (monkeys and rabbits) Efficacy data in three different Alzheimer’s models, all showing promising results • Transgenic mice • Aβ-immunodepl
Slide 23: Alzinova's ALZ-101 Phase 1b-study
Alzinova’s ALZ-101 Phase 1b-study ©2023 Alzinova AB (publ), All rights reserved
Slide 24: ALZ-101 Phase 1b clinical study in patients with Alzheimer's disease
ALZ-101 Phase 1b clinical study in patients with Alzheimer’s disease Study: Double-blind, randomized, placebo-controlled study on safety, tolerability and immunogenicity. Part A - ALZ-101 (125 and 250 μg) or placebo, given at weeks 0, 4, 8 and 16, if not eligible for Part B, follow-up for additional
Slide 25: Strong data in Phase 1b Study
Strong data in Phase 1b Study Interim analysis - good safety and tolerability with a clear immune response - 26 subjects included - treated with at least 3 doses of ALZ-101 (125 and 250 μg) or placebo - increasing antibody levels with number of doses given Top-line results - The study met the primar
Slide 26: Phase 2 preparations
Phase 2 preparations Interactions with Regulatory Authorities – FDA and EMA Comprehensive preparation work - Scalable manufacturing process - Study design and protocol development - CRO and site selection - Fast track application based on Phase 1b data - Intellectual property strategy work - Manufac
Slide 27: Corporate & Finance
Corporate & Finance ©2023 Alzinova AB (publ), All rights reserved
Slide 28: Experienced management team
Experienced management team Kristina Torfgård, PhD Anders Sandberg, PhD Håkan Skogström Chief Executive Officer Chief Scientific Officer Chief Financial Officer 30 years experience from leading roles Co-Founder >25 years experience from leading in pharma and biopharma industry >20 years experience i
Slide 29: Board of Directors with extensive pharma and biopharma experience
Julian Aleksov Anders Blom Per-Göran Gillberg, PhD Clas Malmeström, MD, PhD Chairman Member Member Member >25 years experience in finance and >25 years experience in international 35 years experience in drug development Chief physician MS-center, neuro- international development within finance and b
Slide 30: Capitalization table, summary of shares and options
Capitalization table, summary of shares and options Shareholders, as per 29 September 2023: Name No. of shares Capital, % Maida Vale Capital AB 6,747,686 15.15% Försäkrings AB Avanza Pension 3,223,681 7.24% Nordnet Pensionsförsäkring AB 2,229,751 5.01% Patrik Ahlvin 1,004,750 2.26% Sara Gjertz 877,3
Slide 31: Financial information – Key figures Jan-Sep 2023
Financial information Key figures, for Jan-Sep 2023 (Jan-Sep 2022) Total balance sheet Cash balance Cashflow Result Equity ratio 126 33 1 -12 94% (115) (39) (10) (-8) (96%) MSEK MSEK MSEK MSEK • Mainly invested in capitalized costs for R&D, focus on present ALZ-101 phase 1 study and preparing ALZ-10
Slide 32: Roadmap & value inflection points
Roadmap & value inflection points Phase 1b study ALZ-101 Phase 1b study top-line results interim data ALZ-101 Phase 1b study results ALZ-101 Phase 2 Study 2023 Q2 2023 Q4 2024 Q1 2024+ 2023 Q2 2024+ 2024+ Phase 1b study extension Fast track application ALZ-101 ALZ-201 Phase 1b Study Cash to finance
Slide 33: Investment highlights
Investment highlights Alzinova’s goal is to enable Alzheimer’s patients to live an independent and active life. Alzinova’s lead candidate, ALZ-101, is a therapeutic vaccine against Alzheimer’s in clinical development with a phase 1b study in patients. Based on the same technology, Alzinova is also d
Slide 34: Alzinova
CEO Kristina Torfgård Alzinova Email: [email protected] Phone: +46 70 846 79 75 www.alzinova.com https://www.linkedin.com/company/alzinova-ab/ ©2023 Alzinova AB (publ), All rights reserved